Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 293

1.

A Peripheral Blood Gene Expression Signature to Diagnose Subclinical Acute Rejection.

Zhang W, Yi Z, Keung KL, Shang H, Wei C, Cravedi P, Sun Z, Xi C, Woytovich C, Farouk S, Huang W, Banu K, Gallon L, Magee CN, Najafian N, Samaniego M, Djamali A, Alexander SI, Rosales IA, Smith RN, Xiang J, Lerut E, Kuypers D, Naesens M, O'Connell PJ, Colvin R, Menon MC, Murphy B.

J Am Soc Nephrol. 2019 Jul 5. pii: ASN.2018111098. doi: 10.1681/ASN.2018111098. [Epub ahead of print]

PMID:
31278196
2.

Persistent primary cytomegalovirus infection in a kidney transplant recipient: Multi-drug resistant and compartmentalized infection leading to graft loss.

Andrei G, Van Loon E, Lerut E, Victoor J, Meijers B, Bammens B, Sprangers B, Gillemot S, Fiten P, Opdenakker G, Lagrou K, Kuypers D, Snoeck R, Naesens M.

Antiviral Res. 2019 Aug;168:203-209. doi: 10.1016/j.antiviral.2019.06.004. Epub 2019 Jun 15.

PMID:
31212020
3.

Specificity, strength, and evolution of pretransplant donor-specific HLA antibodies determine outcome after kidney transplantation.

Senev A, Lerut E, Van Sandt V, Coemans M, Callemeyn J, Sprangers B, Kuypers D, Emonds MP, Naesens M.

Am J Transplant. 2019 May 6. doi: 10.1111/ajt.15414. [Epub ahead of print]

PMID:
31062492
4.

Delayed bleeding of the Transplant Duodenum After Simultaneous Kidney Pancreas Transplantation: Case Series.

Van Mellaert A, Gillard P, Jochmans I, Demedts I, Sagaert X, Naesens M, Monbaliu D, Kuypers D, Pirenne J, Sprangers B.

Transplantation. 2019 Apr 1. doi: 10.1097/TP.0000000000002718. [Epub ahead of print]

PMID:
30946219
5.

Bone mineral density, bone turnover markers, and incident fractures in de novo kidney transplant recipients.

Evenepoel P, Claes K, Meijers B, Laurent MR, Bammens B, Naesens M, Sprangers B, Pottel H, Cavalier E, Kuypers D.

Kidney Int. 2019 Jun;95(6):1461-1470. doi: 10.1016/j.kint.2018.12.024. Epub 2019 Mar 4.

PMID:
30922664
6.

Histological characteristics of Acute Tubular Injury during Delayed Graft Function predict renal function after renal transplantation.

Pieters TT, Falke LL, Nguyen TQ, Verhaar MC, Florquin S, Bemelman FJ, Kers J, Vanhove T, Kuypers D, Goldschmeding R, Rookmaaker MB.

Physiol Rep. 2019 Mar;7(5):e14000. doi: 10.14814/phy2.14000.

7.

Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study.

Tedesco-Silva H, Pascual J, Viklicky O, Basic-Jukic N, Cassuto E, Kim DY, Cruzado JM, Sommerer C, Adel Bakr M, Garcia VD, Uyen HD, Russ G, Soo Kim M, Kuypers D, Buchler M, Citterio F, Hernandez Gutierrez MP, Bernhardt P, Chadban S; TRANSFORM Investigators.

Transplantation. 2019 Feb 19. doi: 10.1097/TP.0000000000002626. [Epub ahead of print]

PMID:
30801548
8.

Occurrence of Diabetic Nephropathy After Renal Transplantation Despite Intensive Glycemic Control: An Observational Cohort Study.

Coemans M, Van Loon E, Lerut E, Gillard P, Sprangers B, Senev A, Emonds MP, Van Keer J, Callemeyn J, Daniëls L, Sichien J, Verbeke G, Kuypers D, Mathieu C, Naesens M.

Diabetes Care. 2019 Apr;42(4):625-634. doi: 10.2337/dc18-1936. Epub 2019 Feb 14.

PMID:
30765434
9.

Fungal infections in solid organ transplantation: An update on diagnosis and treatment.

Kabir V, Maertens J, Kuypers D.

Transplant Rev (Orlando). 2019 Apr;33(2):77-86. doi: 10.1016/j.trre.2018.12.001. Epub 2018 Dec 13. Review.

PMID:
30579665
10.

Poor Vitamin K Status Is Associated With Low Bone Mineral Density and Increased Fracture Risk in End-Stage Renal Disease.

Evenepoel P, Claes K, Meijers B, Laurent M, Bammens B, Naesens M, Sprangers B, Pottel H, Cavalier E, Kuypers D.

J Bone Miner Res. 2019 Feb;34(2):262-269. doi: 10.1002/jbmr.3608. Epub 2018 Nov 14.

PMID:
30427544
11.

Natural killer cell infiltration is discriminative for antibody-mediated rejection and predicts outcome after kidney transplantation.

Yazdani S, Callemeyn J, Gazut S, Lerut E, de Loor H, Wevers M, Heylen L, Saison C, Koenig A, Thaunat O, Thorrez L, Kuypers D, Sprangers B, Noël LH, Van Lommel L, Schuit F, Essig M, Gwinner W, Anglicheau D, Marquet P, Naesens M.

Kidney Int. 2019 Jan;95(1):188-198. doi: 10.1016/j.kint.2018.08.027. Epub 2018 Nov 3.

12.

Natural history of mineral metabolism, bone turnover and bone mineral density in de novo renal transplant recipients treated with a steroid minimization immunosuppressive protocol.

Evenepoel P, Claes K, Meijers B, Laurent MR, Bammens B, Naesens M, Sprangers B, Cavalier E, Kuypers D.

Nephrol Dial Transplant. 2018 Oct 17. doi: 10.1093/ndt/gfy306. [Epub ahead of print]

PMID:
30339234
13.

Building Kidney Exchange Programmes in Europe-An Overview of Exchange Practice and Activities.

Biró P, Haase-Kromwijk B, Andersson T, Ásgeirsson EI, Baltesová T, Boletis I, Bolotinha C, Bond G, Böhmig G, Burnapp L, Cechlárová K, Di Ciaccio P, Fronek J, Hadaya K, Hemke A, Jacquelinet C, Johnson R, Kieszek R, Kuypers DR, Leishman R, Macher MA, Manlove D, Menoudakou G, Salonen M, Smeulders B, Sparacino V, Spieksma FCR, Valentín MO, Wilson N, van der Klundert J; ENCKEP COST Action.

Transplantation. 2019 Jul;103(7):1514-1522. doi: 10.1097/TP.0000000000002432.

14.

Relationship between In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Systemic Tacrolimus Metabolite/Parent Drug Ratio in Renal Transplant Recipients and Healthy Volunteers.

Vanhove T, de Jonge H, de Loor H, Oorts M, de Hoon J, Pohanka A, Annaert P, Kuypers DRJ.

Drug Metab Dispos. 2018 Nov;46(11):1507-1513. doi: 10.1124/dmd.118.081935. Epub 2018 Aug 30.

PMID:
30166405
15.

Long-term Challenges After Solid Organ Transplantation: Summary of Expert Presentations From the Sandoz 5th Standalone Transplantation Meeting, 2017.

Legendre C, Viebahn R, Fehrman-Ekholm I, Masnou N, Berenguer M, Potena L, Wennberg L, O'Grady J, Epailly E, Diekmann F, Binet I, Schwenger V, Kuypers D, Guthoff M.

Transplantation. 2018 Sep;102(9S Suppl 1):S1-S14. doi: 10.1097/TP.0000000000002316. No abstract available.

PMID:
30113932
16.

Histological picture of antibody-mediated rejection without donor-specific anti-HLA antibodies: Clinical presentation and implications for outcome.

Senev A, Coemans M, Lerut E, Van Sandt V, Daniëls L, Kuypers D, Sprangers B, Emonds MP, Naesens M.

Am J Transplant. 2019 Mar;19(3):763-780. doi: 10.1111/ajt.15074. Epub 2018 Sep 28.

PMID:
30107078
17.

Analyses of the short- and long-term graft survival after kidney transplantation in Europe between 1986 and 2015.

Coemans M, Süsal C, Döhler B, Anglicheau D, Giral M, Bestard O, Legendre C, Emonds MP, Kuypers D, Molenberghs G, Verbeke G, Naesens M.

Kidney Int. 2018 Nov;94(5):964-973. doi: 10.1016/j.kint.2018.05.018. Epub 2018 Jul 24.

PMID:
30049474
18.

In vivo CYP3A4 activity does not predict the magnitude of interaction between itraconazole and tacrolimus from an extended release formulation.

Vanhove T, Annaert P, Knops N, de Loor H, de Hoon J, Kuypers DRJ.

Basic Clin Pharmacol Toxicol. 2019 Jan;124(1):50-55. doi: 10.1111/bcpt.13092. Epub 2018 Aug 14.

PMID:
29989304
19.

The clinical significance of epitope mismatch load in kidney transplantation: A multicentre study.

Daniëls L, Naesens M, Bosmans JL, Abramowicz D, Nagler E, Van Laecke S, Peeters P, Kuypers D, Emonds MP.

Transpl Immunol. 2018 Oct;50:55-59. doi: 10.1016/j.trim.2018.06.006. Epub 2018 Jun 15.

PMID:
29908316
20.

"What do we know about tacrolimus pharmacogenetics in transplant recipients?"

Kuypers DR.

Pharmacogenomics. 2018 May;19(7):593-597. doi: 10.2217/pgs-2018-0035. Epub 2018 Apr 27. No abstract available.

PMID:
29701126
21.

Kuypers and Vanhove reply to 'Was 4β-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?' by Neuhoff and Tucker.

Kuypers DRJ, Vanhove T.

Br J Clin Pharmacol. 2018 Jul;84(7):1622-1623. doi: 10.1111/bcp.13592. Epub 2018 Apr 24. No abstract available.

22.

Ischemia-Induced DNA Hypermethylation during Kidney Transplant Predicts Chronic Allograft Injury.

Heylen L, Thienpont B, Naesens M, Busschaert P, Depreeuw J, Smeets D, Jochmans I, Monbaliu D, Pirenne J, Lerut E, Ghesquiere B, Kuypers D, Lambrechts D, Sprangers B.

J Am Soc Nephrol. 2018 May;29(5):1566-1576. doi: 10.1681/ASN.2017091027. Epub 2018 Apr 2.

23.

Connective tissue growth factor (CTGF) from basics to clinics.

Ramazani Y, Knops N, Elmonem MA, Nguyen TQ, Arcolino FO, van den Heuvel L, Levtchenko E, Kuypers D, Goldschmeding R.

Matrix Biol. 2018 Aug;68-69:44-66. doi: 10.1016/j.matbio.2018.03.007. Epub 2018 Mar 21. Review.

PMID:
29574063
24.

Tacrolimus Formulations and African American Kidney Transplant Recipients: When Do Details Matter?

Kuypers DRJ.

Am J Kidney Dis. 2018 Mar;71(3):302-305. doi: 10.1053/j.ajkd.2017.10.020. No abstract available.

PMID:
29477174
25.

Prospective randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with posttransplant diabetes mellitus after renal transplantation.

Wissing KM, Abramowicz D, Weekers L, Budde K, Rath T, Witzke O, Broeders N, Kianda M, Kuypers DRJ.

Am J Transplant. 2018 Jul;18(7):1726-1734. doi: 10.1111/ajt.14665. Epub 2018 Feb 22.

26.

Pretransplant 4β-hydroxycholesterol does not predict tacrolimus exposure or dose requirements during the first days after kidney transplantation.

Vanhove T, Hasan M, Annaert P, Oswald S, Kuypers DRJ.

Br J Clin Pharmacol. 2017 Nov;83(11):2406-2415. doi: 10.1111/bcp.13343. Epub 2017 Jul 14.

27.

Fexofenadine, a Putative In Vivo P-glycoprotein Probe, Fails to Predict Clearance of the Substrate Tacrolimus in Renal Recipients.

Vanhove T, Bouillon T, de Loor H, Annaert P, Kuypers D.

Clin Pharmacol Ther. 2017 Dec;102(6):989-996. doi: 10.1002/cpt.718. Epub 2017 May 27.

PMID:
28437851
28.

A noninferiority trial comparing a heparin-grafted membrane plus citrate-containing dialysate versus regional citrate anticoagulation: results of the CiTED study.

Meijers B, Metalidis C, Vanhove T, Poesen R, Kuypers D, Evenepoel P.

Nephrol Dial Transplant. 2017 Apr 1;32(4):707-714. doi: 10.1093/ndt/gfw461.

PMID:
28407129
29.

Tubulointerstitial expression and urinary excretion of connective tissue growth factor 3 months after renal transplantation predict interstitial fibrosis and tubular atrophy at 5 years in a retrospective cohort analysis.

Vanhove T, Kinashi H, Nguyen TQ, Metalidis C, Poesen K, Naesens M, Lerut E, Goldschmeding R, Kuypers DRJ.

Transpl Int. 2017 Jul;30(7):695-705. doi: 10.1111/tri.12960. Epub 2017 May 9.

30.

Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients: A Guidance Report and Clinical Checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) Group.

Neuberger JM, Bechstein WO, Kuypers DR, Burra P, Citterio F, De Geest S, Duvoux C, Jardine AG, Kamar N, Krämer BK, Metselaar HJ, Nevens F, Pirenne J, Rodríguez-Perálvarez ML, Samuel D, Schneeberger S, Serón D, Trunečka P, Tisone G, van Gelder T.

Transplantation. 2017 Apr;101(4S Suppl 2):S1-S56. doi: 10.1097/TP.0000000000001651.

PMID:
28328734
31.

Determinants of the Magnitude of Interaction Between Tacrolimus and Voriconazole/Posaconazole in Solid Organ Recipients.

Vanhove T, Bouwsma H, Hilbrands L, Swen JJ, Spriet I, Annaert P, Vanaudenaerde B, Verleden G, Vos R, Kuypers DRJ.

Am J Transplant. 2017 Sep;17(9):2372-2380. doi: 10.1111/ajt.14232. Epub 2017 Apr 8.

32.

Clinical Trials for Immunosuppression in Transplantation: The Case for Reform and Change in Direction.

OʼConnell PJ, Kuypers DR, Mannon RB, Abecassis M, Chadban SJ, Gill JS, Murphy B, Nickerson PW, Schold JD, Stock PG, Seron D, Alloway RR, Bromberg JS, Budde K, Jordan SC, Legendre C, Lefaucheur C, Sarwall M, Segev DL, Stegall MD, Tullius SG, Wong G, Woodle ES, Ascher N, Morris RE.

Transplantation. 2017 Jul;101(7):1527-1534. doi: 10.1097/TP.0000000000001648.

PMID:
28207630
33.

Response to: 'Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance'.

Vanhove T, Annaert P, Kuypers DRJ.

Br J Clin Pharmacol. 2017 Jun;83(6):1353-1356. doi: 10.1111/bcp.13249. Epub 2017 Feb 20. No abstract available.

34.

Advancing Transplantation: New Questions, New Possibilities in Kidney and Liver Transplantation.

Wadström J, Ericzon BG, Halloran PF, Bechstein WO, Opelz G, Serón D, Grinyó J, Loupy A, Kuypers D, Mariat C, Clancy M, Jardine AG, Guirado L, Fellström B, O'Grady J, Pirenne J, O'Leary JG, Aluvihare V, Trunečka P, Baccarani U, Neuberger J, Soto-Gutierrez A, Geissler EK, Metzger M, Gray M.

Transplantation. 2017 Feb;101 Suppl 2S:S1-S41. doi: 10.1097/TP.0000000000001563. No abstract available.

PMID:
28125449
35.

Tacrolimus dose requirements in paediatric renal allograft recipients are characterized by a biphasic course determined by age and bone maturation.

Knops N, Herman J, van Dyck M, Ramazani Y, Debbaut E, van Damme-Lombaerts R, Levtchenko E, van den Heuvel LP, Fieuws S, Kuypers D.

Br J Clin Pharmacol. 2017 Apr;83(4):863-874. doi: 10.1111/bcp.13174. Epub 2016 Dec 13.

36.

Kidney Fibrosis: Origins and Interventions.

Vanhove T, Goldschmeding R, Kuypers D.

Transplantation. 2017 Apr;101(4):713-726. doi: 10.1097/TP.0000000000001608. Review.

PMID:
27941433
37.

Effect of the Direct Oral Anticoagulants Rivaroxaban and Apixaban on the Disposition of Calcineurin Inhibitors in Transplant Recipients.

Vanhove T, Spriet I, Annaert P, Maertens J, Van Cleemput J, Vos R, Kuypers D.

Ther Drug Monit. 2017 Feb;39(1):77-82. doi: 10.1097/FTD.0000000000000356.

PMID:
27861314
38.

Predictive Modeling of Tacrolimus Dose Requirements: "All That Is Gold Does Not Glitter".

Kuypers DR, Vanhove T.

Am J Transplant. 2017 Apr;17(4):1144-1145. doi: 10.1111/ajt.14108. Epub 2016 Dec 9. No abstract available.

39.

Microbiota-Derived Phenylacetylglutamine Associates with Overall Mortality and Cardiovascular Disease in Patients with CKD.

Poesen R, Claes K, Evenepoel P, de Loor H, Augustijns P, Kuypers D, Meijers B.

J Am Soc Nephrol. 2016 Nov;27(11):3479-3487. Epub 2016 May 26.

40.

Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study.

Durrbach A, Pestana JM, Florman S, Del Carmen Rial M, Rostaing L, Kuypers D, Matas A, Wekerle T, Polinsky M, Meier-Kriesche HU, Munier S, Grinyó JM.

Am J Transplant. 2016 Nov;16(11):3192-3201. doi: 10.1111/ajt.13830. Epub 2016 Jun 9.

41.

Drug-drug interactions between immunosuppressants and antidiabetic drugs in the treatment of post-transplant diabetes mellitus.

Vanhove T, Remijsen Q, Kuypers D, Gillard P.

Transplant Rev (Orlando). 2017 Apr;31(2):69-77. doi: 10.1016/j.trre.2016.09.001. Epub 2016 Sep 14. Review.

PMID:
27665059
42.

Incidence of Posttransplantation Diabetes Mellitus in De Novo Kidney Transplant Recipients Receiving Prolonged-Release Tacrolimus-Based Immunosuppression With 2 Different Corticosteroid Minimization Strategies: ADVANCE, A Randomized Controlled Trial.

Mourad G, Glyda M, Albano L, Viklický O, Merville P, Tydén G, Mourad M, Lõhmus A, Witzke O, Christiaans MHL, Brown MW, Undre N, Kazeem G, Kuypers DRJ; Advagraf-based immunosuppression regimen examining new onset diabetes mellitus in kidney transplant recipients (ADVANCE) study investigators.

Transplantation. 2017 Aug;101(8):1924-1934. doi: 10.1097/TP.0000000000001453.

43.

Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance.

Vanhove T, de Jonge H, de Loor H, Annaert P, Diczfalusy U, Kuypers DR.

Br J Clin Pharmacol. 2016 Dec;82(6):1539-1549. doi: 10.1111/bcp.13083. Epub 2016 Sep 20.

44.

Updated Manufacturer and European Medicines Agency Recommendations on the Use of Mycophenolate Acid: Balancing the Risks for Male Allograft Recipients.

Kuypers DR, Van Mieghem T, Meijers B, Claes K.

Transplantation. 2016 Sep;100(9):e50-1. doi: 10.1097/TP.0000000000001342. No abstract available.

PMID:
27472093
45.

Decreased Circulating Sclerostin Levels in Renal Transplant Recipients With Persistent Hyperparathyroidism.

Evenepoel P, Claes K, Viaene L, Bammens B, Meijers B, Naesens M, Sprangers B, Kuypers D.

Transplantation. 2016 Oct;100(10):2188-93. doi: 10.1097/TP.0000000000001311.

PMID:
27379556
46.

Effect of ABCB1 diplotype on tacrolimus disposition in renal recipients depends on CYP3A5 and CYP3A4 genotype.

Vanhove T, Annaert P, Lambrechts D, Kuypers DRJ.

Pharmacogenomics J. 2017 Dec;17(6):556-562. doi: 10.1038/tpj.2016.49. Epub 2016 Jul 5.

PMID:
27378609
47.

Donor-specific antibodies require preactivated immune system to harm renal transplant.

Süsal C, Döhler B, Ruhenstroth A, Morath C, Slavcev A, Fehr T, Wagner E, Krüger B, Rees M, Balen S, Živčić-Ćosić S, Norman DJ, Kuypers D, Emonds MP, Pisarski P, Bösmüller C, Weimer R, Mytilineos J, Scherer S, Tran TH, Gombos P, Schemmer P, Zeier M, Opelz G; A Collaborative Transplant Study Report.

EBioMedicine. 2016 Jul;9:366-371. doi: 10.1016/j.ebiom.2016.06.006. Epub 2016 Jun 5.

48.

Genome-Wide Association Study of Acute Renal Graft Rejection.

Ghisdal L, Baron C, Lebranchu Y, Viklický O, Konarikova A, Naesens M, Kuypers D, Dinic M, Alamartine E, Touchard G, Antoine T, Essig M, Rerolle JP, Merville P, Taupin JL, Le Meur Y, Grall-Jezequel A, Glowacki F, Noël C, Legendre C, Anglicheau D, Broeders N, Coppieters W, Docampo E, Georges M, Ajarchouh Z, Massart A, Racapé J, Abramowicz D, Abramowicz M.

Am J Transplant. 2017 Jan;17(1):201-209. doi: 10.1111/ajt.13912. Epub 2016 Jul 22.

49.

The Influence of Prebiotic Arabinoxylan Oligosaccharides on Microbiota Derived Uremic Retention Solutes in Patients with Chronic Kidney Disease: A Randomized Controlled Trial.

Poesen R, Evenepoel P, de Loor H, Delcour JA, Courtin CM, Kuypers D, Augustijns P, Verbeke K, Meijers B.

PLoS One. 2016 Apr 21;11(4):e0153893. doi: 10.1371/journal.pone.0153893. eCollection 2016.

50.

Metabolism, Protein Binding, and Renal Clearance of Microbiota-Derived p-Cresol in Patients with CKD.

Poesen R, Evenepoel P, de Loor H, Kuypers D, Augustijns P, Meijers B.

Clin J Am Soc Nephrol. 2016 Jul 7;11(7):1136-44. doi: 10.2215/CJN.00160116. Epub 2016 Apr 15.

Supplemental Content

Loading ...
Support Center